z-logo
open-access-imgOpen Access
Utilization of Nivolumab in Adenoid Cystic Carcinoma After Progression on Platinum-Based Chemotherapy
Author(s) -
Diana Maslov,
Katharine Thomas,
Marc Matrana
Publication year - 2021
Publication title -
the permanente journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.445
H-Index - 30
eISSN - 1552-5775
pISSN - 1552-5767
DOI - 10.7812/tpp/20.229
Subject(s) - medicine , adenoid cystic carcinoma , radiation therapy , radiology , nivolumab , paranasal sinuses , biopsy , maxillary sinus , nasal cavity , surgery , carcinoma , pathology , immunotherapy , cancer
Adenoid cystic carcinoma (ACC) is a rare malignant neoplasm within the secretory glands of the head and neck. Clinical findings include a lump on the palate, tongue, or bottom of the mouth. Because symptoms can be mild, patients go for long periods of time without investigation. ACC is diagnosed using histology. Treatment is by surgical resection because there is no effective chemotherapy. Radiation can be effective adjuvant therapy, and proton therapy and stereotactic irradiation can be used for those who are ineligible for surgery. Immunotherapy has clinical activity for those with metastatic head and neck cancers who progress on proton therapy. This case reviews the use of immunotherapy in a patient with ACC.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom